New radiation technique for early-stage lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial compares a newer, more targeted type of radiation (hotspot SABR) with the standard SABR approach for people with early-stage non-small cell lung cancer. The goal is to see if the newer method works just as well or better while possibly reducing side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with early-stage (T1-T3, N0) non-small cell lung cancer that is confirmed by biopsy.
- You are in generally good health (ECOG score 0-2, meaning you can do most daily activities without help).
- If you've had lung cancer before, it was treated more than 6 months ago and is now under control.
- You have not had radiation in the same area of the chest that would interfere with this treatment.
- You do not have certain gene mutations (EGFR or ALK) in your tumor, and you have no history of lung scarring (interstitial lung disease) or autoimmune disease requiring treatment in the last 2 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a precise radiation technique called SABR to treat cancer that has spread to a few spots. It aims to see if this approach can help control the cancer better than usual treatment, especially for lung, prostate, colorectal, or other solid tumors with limited spread.
This study tests whether a focused, high-precision type of radiation can control many cancer spread-out spots (“metastases”) at the same time, while keeping side effects acceptable. It may help people with many metastases live longer or have better disease control by aiming treatment at every treatable spot.
This trial tests a personalized radiation treatment called SBRT for early-stage non-small cell lung cancer that is located in the outer part of the lung and cannot be removed with surgery. The goal is to see if this approach works well for people who cannot have surgery or choose not to.
This study is testing whether giving a higher dose of radiation to the tumour, while still keeping the dose to nearby organs safe, can improve control of the cancer. It's for people with early-stage lung cancer (or a single spot of cancer in the lung from another cancer) who are not suitable for or refuse surgery. The treatment specifically targets tumours that are near the chest wall, where a standard approach might not be safe, and uses a special planning scan to guide the dose.
This trial tests a precise type of radiation (SABR) for breast cancer that has spread to other parts of the body. It aims to see if adding SABR to your regular systemic therapy can help control the tumor in the breast and improve your quality of life.
This trial tests a newer, more precise way of giving radiation for lung cancer tumors that are near the center of the chest. The goal is to see if using a smaller treatment area can reduce side effects while still killing the cancer.
Hear when a new Stage I Lung Cancer AJCC v8 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.